



## Lampiran 2. Surat Ijin Penelitian



Nomor : 1847 /B/RSI-SA/VII/2020  
Lamp : -  
Hal : Ijin Penelitian

Semarang, 10 Juli 2020 M  
18 Dzulqo'dah 1441 H

Kepada Yth  
Dekan  
Fakultas Kedokteran  
UNIVERSITAS ISLAM SULTAN AGUNG  
Di Semarang

Assalamu'alaikum Wr.Wb.

Teriring rasa syukur semoga limpahan kasih sayang Allah SWT menyertai didalam melaksanakan tugas dan pengabdian kita. Aamiin.

Menjawab surat Ketua Prodi Farmasi Unissula nomor : 035 / KTI / SA-K-Fa / VI / 2020 perihal permohonan penelitian di Rumah Sakit Islam Sultan Agung Semarang, maka dengan ini kami sampaikan bahwa Direktur Pendidikan & Penunjang Medis RSI Sultan Agung memberikan ijin mahasiswa berikut :

Nama	: Nada Nasiroh Munjijah.
NIM	: 33101600459
Program Studi	: Farmasi.
Fakultas	: Fakultas Kedokteran.
Universitas	: Universitas Islam Sultan Agung Semarang.
Judul Penelitian	: Analisis Pengaruh Clinical Pathway Terhadap Blaya Riil Pada Pasien Penyakit Stoke Di Era Jaminan Kesehatan Nasional (Studi Kasus di RS Islam Sultan Agung Semarang).

Untuk melakukan penelitian di bagian Instalasi Rekam Medik , bagian Casemix dan Pengolahan Klaim Pasien Rumah Sakit Islam Sultan Agung Semarang.

Demikian, atas perhatian dan kerjasamanya kami ucapkan terima kasih.

Billahittaufiq wal hidayah

Wassalamu'alaikum Wr. Wb.

RSI SULTAN AGUNG SEMARANG  
YAYASAN BADAN WAKAF SULTAN AGUNG



*Dr. Minidjan Fasitasari, M. Sc. Sp. GK.*  
Direktur Pendidikan & Penunjang Medis

Tembusan

1. Ka. Instalasi Rekam Medis.
2. Penjab Rekam Medis Rawat Jalan & Rawat Inap..
3. Kasubag Casemix.
4. Penjab Pengolahan Klaim Rawat Inap..
5. Arsip.

### Lampiran 3. Ethical Clearance



KOMITE ETIK PENELITIAN KESEHATAN  
HEALTH RESEARCH ETHICS COMMITTEE  
RSI SULTAN AGUNG  
KEPK RSI SULTAN AGUNG

KETERANGAN LAYAK ETIK  
DESCRIPTION OF ETHICAL EXEMPTION  
"ETHICAL EXEMPTION"

No. 08/EC/KEPK/2020

Protokol penelitian yang diusulkan oleh :  
*The research protocol proposed by*

Peneliti utama : Nada Nasiroh Munjiyah.  
*Principal In Investigator*

Nama Institusi : Universitas Islam Sultan Agung Semarang  
*Name of Institution*

Dengan Judul  
*Title*

**"Analisis Pengaruh Clinical Pathway Terhadap Biaya Riil Pada Pasien Penyakit Stroke Di Era Jaminan Kesehatan Nasional (Studi Kasus di RS Islam Sultan Agung Semarang)"**  
*"The Analysis of the Effect Clinical Pathway on Real Costs in Stroke Patients in the Era of National Health Insurance (Case Study in Sultan Agung Islamic Hospital Semarang)"*

Dinyatakan layak etik sesuai 7 (tujuh) Standar WHO 2011, yaitu 1) Nilai Sosial, 2) Nilai Ilmiah, 3) Pemerataan Beban dan Manfaat, 4) Risiko, 5) Bujukan/Eksploitasi, 6) Kerahasiaan dan Privacy, dan 7) Persetujuan Setelah Penjelasan, yang merujuk pada Pedoman CIOMS 2016. Hal ini seperti yang ditunjukkan oleh terpenuhinya indikator setiap standar.

*Declared to be ethically appropriate in accordance to 7 (seven) WHO 2011 Standards, 1)Social Values, 2)Scientific Values, 3)Equitable Assessment and Benefits, 4)Risks, 5)Persuasion/Exploitation, 6)Confidentiality and Privacy, and 7)Informed Consent, referring to the 2016 CIOMS Guidelines. This is as indicated by the fulfillment of the indicators of each standard.*

Pernyataan Laik Etik ini berlaku selama kurun waktu tanggal 9 Juli 2020 sampai dengan tanggal 9 Juli 2021.

*This declaration of ethics applies during the period July 9, 2020 until July 9, 2021.*

July 9, 2020  
Chairperson



YAYASAN BADAN WAKAF SULTAN AGUNG  
RSI SULTAN AGUNG  
ISLAMIC TEACHING HOSPITAL  
Kerjasama Sesuai Prinsip Syariah  
SEMARANG  
Dr. **Aziz Rosidi**

#### Lampiran 4. Analisis Data Dengan SPSS

##### a. Analisis Deskripsi Karakteristik Pasien

##### Stroke

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Iskemik	159	98.1	98.1	98.1
Hemoragik	3	1.9	1.9	100.0
Total	162	100.0	100.0	

##### Jenis Kelamin

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Perempuan (Stroke Iskemik)	62	38.3	38.3	38.3
Laki-Laki (Stroke Iskemik)	97	59.3	59.3	97.5
Laki-Laki (Stroke Hemoragik)	2	1.9	1.9	99.4
Perempuan (Stroke Hemoragik)	1	.6	.6	100.0
Total	162	100.0	100.0	

##### Usia

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid 41-50th (Stroke Iskemik)	23	14.2	14.2	14.2
51-60th (Stroke Iskemik)	56	34.6	34.6	48.8
61-70th (Stroke Iskemik)	54	33.3	33.3	82.1
>70th (Stroke Iskemik)	26	16.0	16.0	98.1
51-60th (Stroke Hemoragik)	1	.6	.6	98.8
61-7th (Stroke Hemoragik)	2	1.2	1.2	100.0
Total	162	100.0	100.0	

**Tingkat Keparahan Dengan Kode INA-CBG's**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	G-4-13-III	3	1.9	1.9	1.9
	G-4-14-I	28	17.3	17.3	19.1
	G-4-14-II	118	72.8	72.8	92.0
	G-4-14-III	13	8.0	8.0	100.0
	Total	162	100.0	100.0	

**Hak Kelas Perawatan**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	I (Stroke Iskemik)	43	26.5	26.5	26.5
	II (Stroke Iskemik)	39	24.1	24.1	50.6
	III (Stroke Iskemik)	77	47.5	47.5	98.1
	II (Stroke Hemoragik)	1	.6	.6	98.8
	III (Stroke Hemoragik)	2	1.2	1.2	100.0
	Total	162	100.0	100.0	

**LOS**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	<5 Hari (Stroke Iskemik)	84	51.9	51.9	51.9
	5 Hari (Stroke Iskemik)	39	24.1	24.1	75.9
	>5 Hari (Stroke Iskemik)	36	22.2	22.2	98.1
	<9 Hari (Stroke Hemoragik)	2	1.2	1.2	99.4
	>9 Hari (Stroke Hemoragik)	1	.6	.6	100.0
	Total	162	100.0	100.0	

**GDS**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	<200 (Stroke Iskemik)	128	79.0	79.0	79.0
	>200 (Stroke Iskemik)	31	19.1	19.1	98.1
	<200 (Stroke Hemoragik)	3	1.9	1.9	100.0

Total	162	100.0	100.0
-------	-----	-------	-------

### Jumlah Jenis Obat Tambahan

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Tidak	22	13.6	13.6	13.6
1-5 Jenis (Iskemik)	57	35.2	35.2	48.8
>5 Jenis (Iskemik)	80	49.4	49.4	98.1
1-5 Jenis (Hemoragik)	1	.6	.6	98.8
>5 Jenis (Hemoragik)	2	1.2	1.2	100.0
Total	162	100.0	100.0	

### Jumlah Penyakit Penyerta

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Tidak Ada Penyakit Penyerta	35	21.6	21.6	21.6
1 Penyakit Penyerta	38	23.5	23.5	45.1
>1 Penyakit Penyerta	86	53.1	53.1	98.1
1 Penyakit Penyerta (H)	2	1.2	1.2	99.4
>1 Penyakit Penyerta (H)	1	.6	.6	100.0
Total	162	100.0	100.0	

#### b. Analisis Deskriptif Karakteristik Penyakit Penyerta

##### Satu Penyakit Penyerta

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Tidak Ada	122	75.3	75.3	75.3
Dislipidemia	7	4.3	4.3	79.6
Leukositosis	1	.6	.6	80.2
Hipertensi	23	14.2	14.2	94.4
Diabetes Mellitus	4	2.5	2.5	96.9
Hipokalemia	3	1.9	1.9	98.8
Hipertensi (H)	2	1.2	1.2	100.0
Total	162	100.0	100.0	

### Lebih Dari Satu Penyakit Penyerta

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Tidak Ada	74	45.7	45.7	45.7
	Diabetes Mellitus, Hipokalemia, Hiperuricemia	1	.6	.6	46.3
	Hipertensi, Diabetes Mellitus, Dislipidemia	10	6.2	6.2	52.5
	Typhoid Fever, Hipertensi, Dislipidemia	1	.6	.6	53.1
	Hipertensi, Diabetes Mellitus, Dislipidemia, Hiperuricemia	4	2.5	2.5	55.6
	HIPERTENSI, DISLIPIDEMIA, HIPERURICEMIA	3	1.9	1.9	57.4
	DIABETES MELLITUS, HIPERTENSI, DISLIPIDEMIA	1	.6	.6	58.0
	HIPERTENSI, DISLIPIDEMIA	20	12.3	12.3	70.4
	DISLIPIDEMIA, HIPERURICEMIA	4	2.5	2.5	72.8
	HIPERTENSI, HIPERURICEMIA	3	1.9	1.9	74.7
	DISLIPIDEMIA, HIPERURICEMIA, DIABETES MELLITUS	1	.6	.6	75.3
	DIABETES MELLITUS, ISCHEMIC HEART DISEASE, HIPOGLIKEMIA	1	.6	.6	75.9
	ANEMIA, HIPOALBUMIN, GASTROENTERITIS, HIPERURICEMIA	1	.6	.6	76.5
	HIPERTENSI, DIABETES MELLITUS	10	6.2	6.2	82.7
	DIABETES MELLITUS, DISLIPIDEMIA	5	3.1	3.1	85.8

DISLIPIDEMIA, HIPERTENSI, ANEMIA, HIPERURICEMIA, GASTROENTERITIS	1	.6	.6	86.4
HIPERTENSI, DISLIPIDEMIA, HIPOKALEMIA	5	3.1	3.1	89.5
HIPERTENSI, ANEMIA, HIPOALBUMIN	1	.6	.6	90.1
HIPERTENSI, DISLIPIDEMIA, ANEMIA	2	1.2	1.2	91.4
ANEMIA, HIPOKALEMIA	1	.6	.6	92.0
DISLIPIDEMIA, LEUKOSITOSIS	1	.6	.6	92.6
HIPOKALEMIA, HIPERTENSI, DIABETES MELLITUS, DISLIPIDEMIA	1	.6	.6	93.2
ANEMIA, HIPERURICEMIA, HIPERTENSI	1	.6	.6	93.8
HIPERTENSI, DISLIPIDEMIA, GASTROENTERITIS	1	.6	.6	94.4
HIPERTENSI, DISLIPIDEMI, LEUKOSITOSIS	1	.6	.6	95.1
HIPERTENSI, HIPOGLIKEMI	2	1.2	1.2	96.3
HIPERTENSI, DISLIPIDEMIA, ANEMIA, DIABETES MELLITUS	1	.6	.6	96.9
HIPERTENSI, ANEMIA	1	.6	.6	97.5
HIPERTENSI, HIPOKALEMIA	2	1.2	1.2	98.8
DIABETES MELLITUS, HIPERTENSI, HIPOKALEMIA	1	.6	.6	99.4
HIPERTENSI, DISLIPIDEMIA (h)	1	.6	.6	100.0
Total	162	100.0	100.0	



## c. Analisis Deskriptif Karakteristik Jenis Obat Tambahan

**Obat Hipolipidemik**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Tidak	74	45.7	45.7	45.7
	Atorvasatatin	27	16.7	16.7	62.3
	Fenofibrate	21	13.0	13.0	75.3
	Simvastatin	18	11.1	11.1	86.4
	Atorvastatin-Fenofibrate	19	11.7	11.7	98.1
	Atorvastatin (H)	1	.6	.6	98.8
	Tidak (H)	2	1.2	1.2	100.0
	Total	162	100.0	100.0	

**Obat Saluran Pencernaan**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Tidak	61	37.7	37.7	37.7
	Ranitidin	36	22.2	22.2	59.9
	Lansoprazole	9	5.6	5.6	65.4
	Sucralfat	1	.6	.6	66.0
	Omeprazole	16	9.9	9.9	75.9
	Ondasentrone	2	1.2	1.2	77.2
	New Diatab	1	.6	.6	77.8
	Ulsidex	1	.6	.6	78.4
	Lansoprazole, Sucralfat	3	1.9	1.9	80.2
	Omeprazole, Ranitidin	2	1.2	1.2	81.5
	Sucralfat, Buscopan, Ranitidin, Lansoprazole	1	.6	.6	82.1
	Lansoprazole, Ranitidin	1	.6	.6	82.7
	Ranitidin, New Diatab	2	1.2	1.2	84.0
	Sucralfat, Ranitidin	1	.6	.6	84.6
	Ranitidin, Dulcolac	1	.6	.6	85.2
	Mucosta, Lansoprazole, Omeprazole	1	.6	.6	85.8
	Ranitidin, Ondansentrone	4	2.5	2.5	88.3
	Lansoprazole, Antasid	1	.6	.6	88.9
	Ondansentrone, New Diatab, Ranitidin	1	.6	.6	89.5
	Lansoprazole, Omeprazole	1	.6	.6	90.1

Lansoprazole, Ondansetrone	2	1.2	1.2	91.4
Omeprazole, Bisacodyl, Sucralfat, Dulcolac	1	.6	.6	92.0
Omeprazole, Lactulax	1	.6	.6	92.6
Sucralfat, Omeprazole	2	1.2	1.2	93.8
Ranitidin, Ondansetrone, Lansoprazole, Sucralfat, New Diatab	1	.6	.6	94.4
Lansoprazole, Pantoprazole, Sucralfat	1	.6	.6	95.1
Ranitidin, Natrium Bicarbonat	1	.6	.6	95.7
Lansoprazole, New Diatab, Aminoral	1	.6	.6	96.3
Lansoprazole, Mucosta, Ondansetrone, Sucralfat	1	.6	.6	96.9
Omeprazole, Ondansetrone	1	.6	.6	97.5
Lansoprazole, Sucralfat, Mucosta, Omeprazole	1	.6	.6	98.1
Tidak (H)	1	.6	.6	98.8
Dulcolac-Lansoprazole (H)	1	.6	.6	99.4
Ranitidin, Dulcolac (H)	1	.6	.6	100.0
Total	162	100.0	100.0	

### Obat Vitamin, Mineral, Suplemen & Anti Anemia

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Tidak	38	23.5	23.5	23.5
	Asam Folac	7	4.3	4.3	27.8
	Neurodex	2	1.2	1.2	29.0
	Mecobalamin	49	30.2	30.2	59.3
	Neurosanbe	18	11.1	11.1	70.4
	Curcuma	1	.6	.6	71.0
	Bio ATP	1	.6	.6	71.6
	Fermia	1	.6	.6	72.2
	Lacbon	1	.6	.6	72.8
	Asam Folac, Neurodex	1	.6	.6	73.5

Mecobalamin, Asam Folac	2	1.2	1.2	74.7
Asam Folac, Neurosanbe	2	1.2	1.2	75.9
Mecobalamin, Neurosanbe	12	7.4	7.4	83.3
Asam Folac, Mecobalamin, Glucosamin, Zinc	1	.6	.6	84.0
Mecobalamin, Bio ATP	4	2.5	2.5	86.4
Mecobalamin, Neurosanbe, Vitamin B1	1	.6	.6	87.0
L-Bio, Fermia, Zinc	1	.6	.6	87.7
Mecobalamin, Bio ATP, Neurosanbe	1	.6	.6	88.3
Neurosanbe, Hemafort	1	.6	.6	88.9
Curcuma, Neurosanbe	1	.6	.6	89.5
Mecobalamin, Bio ATP, Tromboles, Neurosanbe	1	.6	.6	90.1
Mecobalamin, Asam FOLac, QTen	1	.6	.6	90.7
Neurobion, Fermia, Mecobalamin	1	.6	.6	91.4
Hemobion, Asam FOLac, Vitamin B Complex, CURcuma, mecobalamin	1	.6	.6	92.0
Asam FOLac, Fermia	1	.6	.6	92.6
Mecobalamin, Sangobion, Asam Folac	2	1.2	1.2	93.8
Neurosanbe, Hemobion	1	.6	.6	94.4
Asam Folac, Curcuma	1	.6	.6	95.1
Mecobalamin, ZInc	1	.6	.6	95.7
Neurodex, Asam Folac, Vitamin C, Fermia	1	.6	.6	96.3
Folavit, Neurosanbe	1	.6	.6	96.9
Neurosanbe, Anemolat, Bio ATP	1	.6	.6	97.5
Mecobalamin, Neulin PS	1	.6	.6	98.1
Neurosanbe (H)	2	1.2	1.2	99.4
Tidak (H)	1	.6	.6	100.0

Total	162	100.0	100.0
-------	-----	-------	-------

### Obat Analgetik

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Tidak	111	68.5	68.5	68.5
	Paracetamol	25	15.4	15.4	84.0
	Ketorolac	5	3.1	3.1	87.0
	Meloxicam	3	1.9	1.9	88.9
	Norages	1	.6	.6	89.5
	Tramadol	3	1.9	1.9	91.4
	Ibuprofen	3	1.9	1.9	93.2
	Eterocoxib	1	.6	.6	93.8
	Ketorolac-Eterocoxib	1	.6	.6	94.4
	Norages, Paracetamol, Ketorolac	1	.6	.6	95.1
	Tramadol, Paracetamol	1	.6	.6	95.7
	Ketorolac, Dexketoprofen	2	1.2	1.2	96.9
	Tramadol, Ketorolac	1	.6	.6	97.5
	Ketorolac, Paracetamol	1	.6	.6	98.1
	Paracetamol (H)	1	.6	.6	98.8
	Tramadol, Paracetamol (H)	1	.6	.6	99.4
	Tidak (H)	1	.6	.6	100.0
	Total	162	100.0	100.0	

### Obat Antibiotik

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Tidak	109	67.3	67.3	67.3
	Ceftriaxone	15	9.3	9.3	76.5
	Cefadroxil	2	1.2	1.2	77.8
	Clindamycin	1	.6	.6	78.4
	Levofloxacin	1	.6	.6	79.0
	Cefixime	3	1.9	1.9	80.9
	Metronidazole	3	1.9	1.9	82.7
	Cefotaxime	2	1.2	1.2	84.0
	Amoxicillin	1	.6	.6	84.6
	Rovadin	1	.6	.6	85.2
	Newspar	1	.6	.6	85.8
	Ceftriaxone, Cefadroxil	4	2.5	2.5	88.3

Clindamycin- Levofloxacin	1	.6	.6	88.9
Ceftriaxone, Cefixime	8	4.9	4.9	93.8
Cefixime, Metronidazole	1	.6	.6	94.4
Cefotaxime, Cefixime	3	1.9	1.9	96.3
Ceftriaxone, Metronidazole, Cefixime	1	.6	.6	96.9
Azitromycin, Cefotaxim	1	.6	.6	97.5
Ceftriaxone, Metronidazole	1	.6	.6	98.1
Tidak (H)	1	.6	.6	98.8
Clindamycin- Levofloxacin (H)	1	.6	.6	99.4
Cefotaxime (H)	1	.6	.6	100.0
Total	162	100.0	100.0	

d. Lampiran Keseluruhan Penggunaan Obat Tambahan

Kelas Terapi	Stroke	Nama Obat	Jumlah (N)	Persentase (%)	
Antidiabetik	Iskemik	Acarbose	3	1.9	
		Glimepiride	1	0.6	
		Metformin	6	3.7	
		Gliquidone	1	0.6	
		Diamicon MR	1	0.6	
		Glimepiride & Metformin	5	3.1	
		Diamicon MR & Metformin	2	1.2	
		Metformin, Glimepirid & Acarbose	1	0.6	
		Hemoragik	-	-	-
		Hipolipidemik	Iskemik	Atorvasatatin	27
Fenofibrate	21			13	
Simvastatin	18			11.1	
Atorvastatin-Fenofibrate	19			11.7	
Hemoragik	Atorvastatin		1	0.6	
Gout	Iskemik	Allopurinol	39	24.1	
	Hemoragik	-	-	-	
Saluran Pencernaan	Iskemik	Ranitidin	36	22.2	
		Lansoprazole	9	5.6	
		Sucralfat	1	0.6	

Omeprazole	16	9.9
Ondasentrone	2	1.2
New Diatab	1	0.6
Ulsidex	1	0.6
Lansoprazole, Sucralfat	3	1.9
Omeprazole, Ranitidin	2	1.2
Sucralfat, Buscopan, Ranitidin, Lansoprazole	1	0.6
Lansoprazole, Ranitidin	1	0.6
Ranitidin, New Diatab	2	1.2
Sucralfat, Ranitidin	1	0.6
Ranitidin, Dulcolac	1	0.6
Mucosta, Lansoprazole, Omeprazole	1	0.6
Ranitidin, Ondansentrone	4	2.5
Lansoprazole, Antasid	1	0.6
Ondansentrone, New Diatab, Ranitidin	1	0.6
Lansoprazole, Omeprazole	1	0.6
Lansoprazole, Ondansentrone	2	1.2
Omeprazole, Bisacodyl, Sucralfat, Dulcolac	1	0.6
Omeprazole, Lactulax	1	0.6
Sucralfat, Omeprazole	2	1.2
Ranitidin, Ondansentrone, Lansoprazole, Sucralfat, New Diatab	1	0.6
Lansoprazole, Pantoprazole, Sucralfat	1	0.6
Ranitidin, Natrium Bicarbonat	1	0.6
Lansoprazole, New Diatab, Aminoral	1	0.6
Lansoprazole, Mucosta, Ondansentrone, Sucralfat	1	0.6
Omeprazole, Ondansentrone	1	0.6
Lansoprazole, Sucralfat, Mucosta, Omeprazole	1	0.6

Hemoragik	Dulcolac-Lansoprazole (H)	1	0.6
	Ranitidin, Dulcolac (H)	1	0.6
Antiplatelet, Antikoagilan & Fibrinolitik (Trombolitik)	Miniaspi	12	7.4
	Clopidogrel	4	2.5
	Arixtra	5	3.1
	Miniaspi-Clopidogrel	4	2.5
	Tarontal	6	3.7
	Arixtra, Clopidogrel, Warfarin	1	0.6
Hemoragik	-	-	-
Vitamin, Mineral, Suplemen & Anti Anemia	Asam Folac	7	4.3
	Neurodex	2	1.2
	Mecobalamin	49	30.2
	Neurosanbe	18	11.1
	Curcuma	1	0.6
	Bio ATP	1	0.6
	Fermia	1	0.6
	Lacbon	1	0.6
	Asam Folac, Neurodex	1	0.6
	Mecobalamin, Asam Folac	2	1.2
	Asam Folac, Neurosanbe	2	1.2
	Mecobalamin, Neurosanbe	12	7.4
	Asam Folac, Mecobalamin,	1	0.6
	Glucosamin, Zinc		
	Mecobalamin, Bio ATP	4	2.5
	Mecobalamin, Neurosanbe, Vitamin B1	1	0.6
	L-Bio, Fermia, Zinc	1	0.6
	Mecobalamin, Bio ATP, Neurosanbe	1	0.6
	Neurosanbe, Hemafort	1	0.6
	Curcuma, Neurosanbe	1	0.6
	Mecobalamin, Bio ATP, Tromboles, Neurosanbe	1	0.6
	Mecobalamin, Asam FOLac, QTen	1	0.6
	Neurobion, Fermia, Mecobalamin	1	0.6
Hemobion, Asam FOLac, Vitamin B	1	0.6	

		Complex, CURcuma, mecobalamin		
		Asam FOLac, Fermia	1	0.6
		Mecobalamin, Sangobion, Asam Folac	2	1.2
		Neurosanbe, Hemobion	1	0.6
		Asam Folac, Curcuma	1	0.6
		Mecobalamin, ZInc	1	0.6
		Neurodex, Asam Folac, Vitamin C, Fermia	1	0.6
		Folavit, Neurosanbe	1	0.6
		Neurosanbe, Anemolat, Bio ATP	1	0.6
		Mecobalamin, Neulin PS	1	0.6
	Hemoragik	Neurosanbe	2	1.2
		Paracetamol	25	15.4
		Ketorolac	5	3.1
		Meloxicam	3	1.9
		Norages	1	0.6
		Tramadol	3	1.9
		Ibuprofen	3	1.9
		Eterocoxib	1	0.6
	Iskemik	Ketorolac-Eterocoxib	1	0.6
Analgetik		Norages, Paracetamol, Ketorolac	1	0.6
		Tramadol, Paracetamol	1	0.6
		Ketorolac, Dexketoprofen	2	1.2
		Tramadol, Ketorolac	1	0.6
		Ketorolac, Paracetamol	1	0.6
	Hemoragik	Paracetamol	1	0.6
		Tramadol, Paracetamol	1	0.6
		Phenytoin	6	3.7
		Gabapentin	12	7.4
		Diazepam	6	3.7
		Clobazam	7	4.3
Anti Epilepsi & Konvulsi (Anti Kejang)	Iskemik	Pregabalin	1	0.6
		Eperison	1	0.6
		Carbamazepine	1	0.6
		Phenytoin, Gabapentin	2	1.2
		Gabapentin, Clobazam	8	4.9
		Clobazam, Pregabalin	1	0.6



		Diazepam, Gabapentin, Eperison	2	1.2		
		Gabapentin, Diazepam	1	0.6		
	Hemoragik	-	-	-		
Elektrolit	Iskemik	KSR	18	11.1		
	Hemoragik	-	-	-		
Kortikosteroid		Dexamethasone	2	1.2		
	Iskemik	Methylprednisolone	2	1.2		
		Dexamethasone, Methyprednisolone	2	1.2		
	Hemoragik	-	-	-		
Antibiotik		Ceftriaxone	15	9.3		
		Cefadroxil	2	1.2		
		Clindamycin	1	0.6		
		Levofloxacin	1	0.6		
		Cefixime	3	1.9		
		Metronidazole	3	1.9		
		Cefotaxime	2	1.2		
		Amoxicillin	1	0.6		
		Rovadin	1	0.6		
		Newspar	1	0.6		
	Iskemik		Ceftriaxone, Cefadroxil	4	2.5	
			Clindamycin- Levofloxacin	1	0.6	
			Ceftriaxone, Cefixime	8	4.9	
			Cefixime, Metronidazole	1	0.6	
			Cefotaxime, Cefixime	3	1.9	
			Ceftriaxone, Metronidazole,	1	0.6	
			Cefixime Azitromycin, Cefotaxim	1	0.6	
			Ceftriaxone, Metronidazole	1	0.6	
		Hemoragik		Clindamycin- Levofloxacin	1	0.6
				Cefotaxime	1	0.6
Psikiatri		Esilgan	1	0.6		
		Amitriptyline	6	3.7		
	Iskemik		Alprazolam	12	7.4	
			Depakote	1	0.6	
			Risperidone	1	0.6	
			Braxidin	1	0.6	
	Helloperidol,	2	1.2			

		Alprazolam		
		Alprazolam, Lorazepam	1	0.6
		Alprazolam, Amitriptyline	2	1.2
		Halooperidol, Amitriptyline	1	0.6
		Depakote, Risperidone	1	0.6
	Hemoragik	-	-	-
		Flunarizine	7	4.3
		Dimenhydrinate	1	0.6
		Betahistine	1	0.6
		Pregabalin	4	2.5
		Flunarizine, Dimenhydrinate	3	1.9
	Iskemik	Betahistine, Flunarizine, Dimenhydrinate	2	1.2
Vertigo & Migrain		Flunarizine, Ergotamin	1	0.6
		Flunarizine, Betahistine	2	1.2
		Flunarizine, betahistine, Ergotamin, Dimenhydrinate, Mertigo	1	0.6
	Hemoragik	Betahistine, Flunarizine, Dimenhydrinate	2	1.2
		Isosorbid Dinitrat	2	1.2
Antiangina	Iskemik	Nitrokaf	5	3.1
		Nitrokaf, Coralan	1	0.6
	Hemoragik	-	-	-
		Trihexyphenidyl	2	1.2
		Levopar	2	1.2
	Iskemik	Donepezil	2	1.2
Parkinson		Trihexyphenidyl, Levopar, Donepezil	1	0.6
		Trihexyphenidyl, Madopar, Levopar	1	0.6
	Hemoragik	Levopar	1	0.6
	Iskemik	Acyclovir	1	0.6
Antivirus	Hemoragik	-	-	-
		Acetylcystein	5	3.1
		OBH	3	1.9
Saluran Nafas	Iskemik	Salbutamol	1	0.6
		Fluimucil	1	0.6
		Aminophyline, Ventoline, Pulmicort,	1	0.6

		Salbutamol, Acetylcystein, OBH, Codein		
		Ventoline, Fluimucil	1	0.6
		Acetylcystein, Ambroxol	1	0.6
		Erdostein, OBH, Acetylsistein	1	0.6
		Ventolin, Bisolvon	1	0.6
		Coribiven	1	0.6
		Acetylcystein, Ventolin	1	0.6
		Ambroxol, Vicilin	1	0.6
	Hemoragik	-	-	-
Hemostatik	Iskemik	Vitamin K1	1	0.6
	Hemoragik	-	-	-
		Kalium Diclofenac	3	1.9
		Eterocoxib	1	0.6
Anti Inflamasi	Iskemik	As. Mefenamat	3	1.9
		Natrium Diclofenac	4	2.5
		Eterocoxib, Cataflam	1	0.6
	Hemoragik	-	-	-
		Rhinos	1	0.6
Antihistamin & Anti Alergi	Iskemik	Loratadine	1	0.6
		Tremenza	1	0.6
		Dimenhydrinate	3	1.9
	Hemoragik	-	-	-
Anti Septik	Iskemik	Borax Gliserin	2	1.2
	Hemoragik	-	-	-
Anti Aritmia	Iskemik	Digoksin	2	1.2
	Hemoragik	-	-	-
Anti Pasmodik	Iskemik	Eperison	2	1.2
	Hemoragik	-	-	-
Vasodilator Perifer	Iskemik	Ergotika	5	3.1
		Papalverin	1	0.6
	Hemoragik	-	-	-
Antifibrinolitik	Iskemik	As. Tranexamat	6	3.7
	Hemoragik	-	-	-

e. Analisis Deskriptif Kegiatan *Clinical Pathway***Kegiatan Diagnosis *Clinical Pathway***

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Dilakukan Pemeriksaan Dokter IGD & Dokter Spesialis Saraf Pada Pasien Stroke Iskemik	159	98.1	98.1	98.1
	Dilakukan Pemeriksaan Dokter IGD & Dokter Spesialis Saraf Pada Pasien Stroke Hemoragik	3	1.9	1.9	100.0
	Total	162	100.0	100.0	

**Pemeriksaan Dokter IGD**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	159	98.1	98.1	98.1
	Ya (H)	3	1.9	1.9	100.0
	Total	162	100.0	100.0	

**Pemeriksaan Dokter Spesialis**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	159	98.1	98.1	98.1
	Ya (H)	3	1.9	1.9	100.0
	Total	162	100.0	100.0	

**Kegiatan Pemeriksaan Penunjang *Clinical Pathway***

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Semua Pemeriksaan Dilakukan (Stroke Iskemik)	159	98.1	98.1	98.1
	Semua Pemeriksaan Dilakukan (Stroke Hemoragik)	3	1.9	1.9	100.0
	Total	162	100.0	100.0	

**Pemeriksaan Brain CT Scan**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	159	98.1	98.1	98.1

Tidak (H)	3	1.9	1.9	100.0
Total	162	100.0	100.0	

#### Pemeriksaan Darah Rutin 1

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	159	98.1	98.1	98.1
	Ya (H)	3	1.9	1.9	100.0
	Total	162	100.0	100.0	

#### Pemeriksaan GDS

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	159	98.1	98.1	98.1
	Ya (H)	3	1.9	1.9	100.0
	Total	162	100.0	100.0	

#### Pemeriksaan Ureum Creatinin

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	159	98.1	98.1	98.1
	Ya (H)	3	1.9	1.9	100.0
	Total	162	100.0	100.0	

#### Pemeriksaan Elektrolit (Na, K, Cl)

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	159	98.1	98.1	98.1
	Ya (H)	3	1.9	1.9	100.0
	Total	162	100.0	100.0	

#### Pemeriksaan Profil Lipid

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	159	98.1	98.1	98.1
	Ya (H)	3	1.9	1.9	100.0
	Total	162	100.0	100.0	

#### Pemeriksaan Asam Urat

		Frequency	Percent	Valid Percent	Cumulative Percent

Valid	Ya	159	98.1	98.1	98.1
	Ya (H)	3	1.9	1.9	100.0
	Total	162	100.0	100.0	

### Pemeriksaan EKG

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	159	98.1	98.1	98.1
	Ya (H)	3	1.9	1.9	100.0
	Total	162	100.0	100.0	

### Pemeriksaan Brain Scan Non Kontras

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Tidak	159	98.1	98.1	98.1
	Ya (H)	3	1.9	1.9	100.0
	Total	162	100.0	100.0	

### Rontgen Thorax

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Tidak	159	98.1	98.1	98.1
	Ya (H)	3	1.9	1.9	100.0
	Total	162	100.0	100.0	

### Kegiatan Visite dan Konsultasi *Clinical Pathway*

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Dilakukan Visite Dokter Spesialis Saraf Pada Pasien Stroke Iskemik	159	98.1	98.1	98.1
	Dilakukan Visite Dokter Spesialis Saraf, Konsultasi Dokter Spesialis Bedah Saraf & KFR Pada Stroke Hemoragik	2	1.2	1.2	99.4
	Dilakukan Visite Dokter Spesialis Saraf, Konsultasi Dokter Spesialis Bedah Saraf Pada Stroke Hemoragik	1	.6	.6	100.0

Total	162	100.0	100.0
-------	-----	-------	-------

### Visite Dokter Spesialis Saraf

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Ya	159	98.1	98.1	98.1
Ya (H)	3	1.9	1.9	100.0
Total	162	100.0	100.0	

### Konsultasi Spesialis Bedah Saraf

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Tidak	159	98.1	98.1	98.1
Ya	3	1.9	1.9	100.0
Total	162	100.0	100.0	

### Dokter Spesialis KFR

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Tidak	159	98.1	98.1	98.1
Ya (H)	2	1.2	1.2	99.4
Tidak (H)	1	.6	.6	100.0
Total	162	100.0	100.0	

### Infus Ringer Laktat

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid 1-5 Hari	124	76.5	76.5	76.5
>5 Hari	35	21.6	21.6	98.1
1-9 Hari (Stroke Hemoragik)	2	1.2	1.2	99.4
>9 Hari (Stroke Hemoragik)	1	.6	.6	100.0
Total	162	100.0	100.0	

### Anti Platelet : Aspilet 80mg

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Tidak	112	69.1	69.1	69.1
1-5 Hari	33	20.4	20.4	89.5
>5 Hari	14	8.6	8.6	98.1
Tidak (Stroke Hemoragik)	3	1.9	1.9	100.0

Total	162	100.0	100.0
-------	-----	-------	-------

### Anti Hipertensi (Inj. Nicardipin) Atau Antihipertensi Peroral

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Tidak (Inj. Nicardipin & Antihipertensi Peroral)	33	20.4	20.4	20.4
Inj. Nicardipin (1-5 Hari)	11	6.8	6.8	27.2
Inj. Nicardipin (>5 Hari)	1	.6	.6	27.8
Antihipertensi Peroral (1-5 Hari)	85	52.5	52.5	80.2
Antihipertensi Peroral (>5 Hari)	20	12.3	12.3	92.6
Inj. Nicardipin & Antihipertensi Peroral 1-5 Hari	9	5.6	5.6	98.1
Inj. Nicardipin & Antihipertensi Peroral 1-9 Hari (Stroke Hemoragik)	1	.6	.6	98.8
Inj. Nicardipin & Antihipertensi Peroral >9 Hari (Stroke Hemoragik)	1	.6	.6	99.4
Antihipertensi Peroral 1-9 Hari (Stroke Hemoragik)	1	.6	.6	100.0
Total	162	100.0	100.0	

### Neuroprotektor (Inj. Citicolin/Piracetam)

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Tidak (Inj. Citicolin & Piracetam)	9	5.6	5.6	5.6
Neuroprotrktor (Inj. Citicolin) 1-3 Hari	93	57.4	57.4	63.0
Neuroprotektor (Inj. Citicolin) >3 Hari	24	14.8	14.8	77.8
Neuroprotektor (Inj. Citicolin) 1-6 Hari Pada Stroke Hemoragik	2	1.2	1.2	79.0



Neuroprotektor (Inj. Piracetam) 1-3 Hari	11	6.8	6.8	85.8
Neuroprotektor (Inj. Piracetam) >3 Hari	4	2.5	2.5	88.3
Inj. Citicolin & Piracetam (1-3 Hari)	11	6.8	6.8	95.1
Inj. Citicolin & Piracetam (>3 Hari)	7	4.3	4.3	99.4
Tidak (Inj. Citicolin & Piracetam) H	1	.6	.6	100.0
Total	162	100.0	100.0	

### Citicolin/Piracetam Peroral

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Tidak (Citicolin & Piracetam Peroral)	28	17.3	17.3	17.3
Citicolin Peroral 1-3 Hari (Stroke Hemoragik)	1	.6	.6	17.9
Citicolin & Piracetam Peroral 1-3 (Stroke Hemoragik)	2	1.2	1.2	19.1
Citicolin Peroral 1-2 Hari	81	50.0	50.0	69.1
Citicolin Peroral >2 Hari	15	9.3	9.3	78.4
Piracetam Peroral 1-2 Hari	28	17.3	17.3	95.7
Piracetam Peroral >2 Hari	1	.6	.6	96.3
Citicolin & Piracetam Peroral 1-2 Hari	4	2.5	2.5	98.8
Citicolin & Piracetam Peroral >2 Hari	2	1.2	1.2	100.0
Total	162	100.0	100.0	

### Insulin

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Tidak	127	78.4	78.4	78.4
1-5 Hari	28	17.3	17.3	95.7
>5Hari	4	2.5	2.5	98.1

Tidak (Stroke Hemoragik)	3	1.9	1.9	100.0
Total	162	100.0	100.0	

### Asam Tranexamat

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Tidak	159	98.1	98.1	98.1
	1-9 Hari	2	1.2	1.2	99.4
	>9 Hari	1	.6	.6	100.0
	Total	162	100.0	100.0	

### Jenis Antihipertensi Peroral

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Tidak	43	26.5	26.5	26.5
	Plasmin	3	1.9	1.9	28.4
	Amlodipin 10mg	28	17.3	17.3	45.7
	Plasmin, Amlodipin 10mg	6	3.7	3.7	49.4
	Amlodipin 10mg, Candesartan	12	7.4	7.4	56.8
	Adalat Oros, Irbesartan	1	.6	.6	57.4
	Amlodipin 10mg, Irbesartan	5	3.1	3.1	60.5
	Plasmin, Amlodipin 10mg, Fluoxetin	1	.6	.6	61.1
	Plasmin, Amlodipin 10mg, candesartan	1	.6	.6	61.7
	Adalat oros, Amlodipin 10mg	1	.6	.6	62.3
	Captopril 25mg, Diltiazem, Concor	1	.6	.6	63.0
	Amlodipin 5mg	3	1.9	1.9	64.8
	Plasmin, Candesartan, Herbesser CD	1	.6	.6	65.4
	Furosemid, Diltiazem	1	.6	.6	66.0
	Concor	3	1.9	1.9	67.9
	Amlodipin 10mg, Furosemid, Plasmin	1	.6	.6	68.5
	Diltiazem	7	4.3	4.3	72.8
	Candesartan, Adalat Oros	2	1.2	1.2	74.1

Adalat Oros, Candesartan, Plasmin, Amlodipin 10mg	1	.6	.6	74.7
Amlodipin 10mg & Amlodipin 5mg	2	1.2	1.2	75.9
Amlodipin 10mg, 5mg & Furosemid	1	.6	.6	76.5
Adalat Oros, Tanapres, Concor	1	.6	.6	77.2
Amlodipin 10mg, Nicardex	3	1.9	1.9	79.0
Amlodipin 10mg, Candesartan, Herbesser CD, Adalat Oros	1	.6	.6	79.6
Amlodipin 10mg, Concor	1	.6	.6	80.2
Plasmin, Concor, Spironolacton, Bioprexium	1	.6	.6	80.9
Candesartan, Clonidin, Adalat Oros	1	.6	.6	81.5
Amlodipin 10mg, Diltiazem	2	1.2	1.2	82.7
Furosemid, Captropil	1	.6	.6	83.3
Nicardex	1	.6	.6	84.0
Plasmin, Amlodipin 10mg, Candesartan, Nicardex	1	.6	.6	84.6
Amlodipin 10mg, Irbesartan, Nicardex	1	.6	.6	85.2
Captropil, Spironolacton, Furosemid	1	.6	.6	85.8
Amlodipin 10mg, Candesartan, Concor	1	.6	.6	86.4
Herbesser CD, Tanapres	1	.6	.6	87.0
Candesartan, Concor, Adalat Oros	1	.6	.6	87.7
Amlodipin 10mg, Candesartan, Spironolactone	1	.6	.6	88.3

Adalat Oros, Tanaprs, Concor, Hydroclorotiazid (HCT)	1	.6	.6	88.9
Tanapres	1	.6	.6	89.5
Candesartan, Concor, Spironolactone	1	.6	.6	90.1
Spironolacton, Tanapres	1	.6	.6	90.7
Candesartan	1	.6	.6	91.4
Amlodipin 10mg, Candesartan, Diltiazem	1	.6	.6	92.0
Adalat Oros	1	.6	.6	92.6
Spironolacton, Concor	1	.6	.6	93.2
Amlodipin 10mg, Candesartan, Spironolacton, Concor, Tanapres	1	.6	.6	93.8
Amlodipin 10mg, Irbesartan, Tanapres, V-Bloc	1	.6	.6	94.4
Candesartan, Herbesser CD, Plasmin, Diltiazem, Furosemid	1	.6	.6	95.1
Amlodipin 10mg, Diltiazem, Nicardex	1	.6	.6	95.7
Amlodipin 10mg, Captropil	1	.6	.6	96.3
Amlodipin 10mg, Candesartan, Nicardex	2	1.2	1.2	97.5
Furosemid, Candesartan, Amlodipin 10mg, Adalat Oros, Diltiazem	1	.6	.6	98.1
Furosemid, Candesartan, Amlodipin 10mg, Adalat Oros, Diltiazem (H)	1	.6	.6	98.8
Amlodipin 10mg (H)	1	.6	.6	99.4
Herbesser CD, Tanapress (H)	1	.6	.6	100.0
Total	162	100.0	100.0	

		<b>Jenis Insulin</b>		Valid Percent	Cumulative Percent
		Frequency	Percent		
Valid	Tidak	128	79.0	79.0	79.0
	Novarapid	2	1.2	1.2	80.2
	Ezelin	4	2.5	2.5	82.7
	Humalog	21	13.0	13.0	95.7
	Novarapid- Lavemir	1	.6	.6	96.3
	Humalog-Ezelin	2	1.2	1.2	97.5
	Apidra-Lavemir	1	.6	.6	98.1
	Tidak (H)	3	1.9	1.9	100.0
	Total	162	100.0	100.0	

## f. Analisis Deskriptif Kegiatan Rehabilitasi/Fisioterapi

		<b>Rehabilitasi/Fisioterapi</b>			
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Tidak (Stroke Iskemik)	26	16.0	16.0	16.0
	1-2 Hari (Stroke Iskemik)	110	67.9	67.9	84.0
	>2 Hari (Stroke Iskemik)	23	14.2	14.2	98.1
	1-2 Hari (Stroke Hemoragik)	2	1.2	1.2	99.4
	>2 Hari (Stroke Hemoragik)	1	.6	.6	100.0
	Total	162	100.0	100.0	

g. Analisis Deskriptif Kegiatan Diluar *Clinical Pathway*

		<b>Obat Diluar <i>Clinical Pathway</i></b>			
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Tidak	49	30.2	30.2	30.2
	Miniaspi 80mg	85	52.5	52.5	82.7
	Clopidogrel	15	9.3	9.3	92.0
	Miniaspi 80mg- Clopidogrel	10	6.2	6.2	98.1
	Tidak (H)	3	1.9	1.9	100.0
	Total	162	100.0	100.0	

**Tindakan Diluar *Clinical Pathway***

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Tidak	121	74.7	74.7	74.7
	Dower Cateter	19	11.7	11.7	86.4
	Pemasangan NGT	3	1.9	1.9	88.3
	Transfusi Darah	1	.6	.6	88.9
	Foto Vertebral Lumbosacral	1	.6	.6	89.5
	Ventilator	1	.6	.6	90.1
	Pemasangan NGT & Dower Cateter	5	3.1	3.1	93.2
	Scan Thorax, Dower Cateter, Pemasangan NGT, Pemasangan ETT, TRansfusi Darah	1	.6	.6	93.8
	Dower Cateter, Transfusi Darah	1	.6	.6	94.4
	Dower Cateter, Transfusi Darah, Pemasangan NGT	3	1.9	1.9	96.3
	Dower Cateter, Pemasangan NGT, Scan Thorax	1	.6	.6	96.9
	Dower Cateter, Pemasangan NGT, pemasangan ETT, Transfusi Darah	1	.6	.6	97.5
	Dower Cateter, Pemasangan NGT, Pemasangan ETT	1	.6	.6	98.1
	Tidak (H)	1	.6	.6	98.8
	Dower Cateter (H)	2	1.2	1.2	100.0
	Total	162	100.0	100.0	

**Peningkatan Kelas Rawat**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Tidak	134	82.7	82.7	82.7
	VIP	14	8.6	8.6	91.4
	I	8	4.9	4.9	96.3
	II	3	1.9	1.9	98.1
	Tidak (H)	3	1.9	1.9	100.0
	Total	162	100.0	100.0	

### Lampiran 5. Hubungan Biaya Riil Dengan *Clinical Pathway*

- a. Hubungan Biaya Riil Dengan Kegiatan Diagnosa *Clinical Pathway*  
 - Uji Normalitas Kolmogorov-Smirnov

#### One-Sample Kolmogorov-Smirnov Test

		Unstandardized Residual
N		162
Normal Parameters <sup>a,b</sup>	Mean	.0000000
	Std. Deviation	2813487.451
		77402
Most Extreme Differences	Absolute	.133
	Positive	.133
	Negative	-.071
Test Statistic		.133
Asymp. Sig. (2-tailed)		.000 <sup>c</sup>

- a. Test distribution is Normal.  
 b. Calculated from data.  
 c. Lilliefors Significance Correction.

- Uji Homogenitas Levene

#### Test of Homogeneity of Variances

		Levene Statistic	df1	df2	Sig.
Biaya Riil	Based on Mean	5.412	1	160	.021
	Based on Median	2.378	1	160	.125
	Based on Median and with adjusted df	2.378	1	135.492	.125
	Based on trimmed mean	5.078	1	160	.026

- Uji Mann-Whitney

#### Mann-Whitney Test

		Ranks		
	Kegiatan Diagnosis <i>Clinical Pathway</i>	N	Mean Rank	Sum of Ranks
Biaya Riil	Dilakukan Pemeriksaan Dokter IGD & Dokter Spesialis Saraf Pada Pasien Stroke Iskemik	159	81.03	12884.00

Dilakukan Pemeriksaan Dokter IGD & Dokter Spesialis Saraf Pada Pasien Stroke Hemoragik	3	106.33	319.00
Total	162		

### Test Statistics<sup>a</sup>

	Biaya Riil
Mann-Whitney U	164.000
Wilcoxon W	12884.000
Z	-.926
Asymp. Sig. (2-tailed)	.355

a. Grouping Variable: Kegiatan Diagnosis *Clinical Pathway*

b. Hubungan Biaya Riil Dengan Kegiatan Pemeriksaan Penunjang *Clinical Pathway*

1. Uji Normalitas Kolmogorov-Smirnov

#### One-Sample Kolmogorov-Smirnov Test

		Unstandardized Residual
N		162
Normal Parameters <sup>a,b</sup>	Mean	.0000000
	Std. Deviation	2813487.451
		77402
Most Extreme Differences	Absolute	.133
	Positive	.133
	Negative	-.071
Test Statistic		.133
Asymp. Sig. (2-tailed)		.000 <sup>c</sup>

a. Test distribution is Normal.

b. Calculated from data.

c. Lilliefors Significance Correction.

2. Uji Homogenitas Levene

#### Test of Homogeneity of Variances

		Levene Statistic	df1	df2	Sig.
Biaya Riil	Based on Mean	5.412	1	160	.021
	Based on Median	2.378	1	160	.125



Based on Median and with adjusted df	2.378	1	135.492	.125
Based on trimmed mean	5.078	1	160	.026

### 3. Uji Mann-Whitney

#### Mann-Whitney Test

		Ranks		
	Kegiatan Pemeriksaan Penunjang <i>Clinical Pathway</i>	N	Mean Rank	Sum of Ranks
Biaya Riil	Semua Pemeriksaan Dilakukan (Stroke Iskemik)	159	81.03	12884.00
	Semua Pemeriksaan Dilakukan (Stroke Hemoragik)	3	106.33	319.00
Total		162		

#### Test Statistics<sup>a</sup>

	Biaya Riil
Mann-Whitney U	164.000
Wilcoxon W	12884.000
Z	-.926
Asymp. Sig. (2-tailed)	.355

a. Grouping Variable: Kegiatan Pemeriksaan Penunjang *Clinical Pathway*

a. Hubungan Biaya *Riil* Dengan Kegiatan Visite & Konsultasi Dokter *Clinical Pathway*

- Uji Normalitas Kolmogorov-Smirnov

#### One-Sample Kolmogorov-Smirnov Test

		Unstandardized Residual
N		162
Normal Parameters <sup>a,b</sup>	Mean	.0000000
	Std. Deviation	2793465.271
		67983
Most Extreme Differences	Absolute	.131
	Positive	.131

Negative	-.071
Test Statistic	.131
Asymp. Sig. (2-tailed)	.000 <sup>c</sup>

- a. Test distribution is Normal.  
 b. Calculated from data.  
 c. Lilliefors Significance Correction.

- Uji Homogenitas Levene

#### Test of Homogeneity of Variances

		Levene Statistic	df1	df2	Sig.
Biaya Riil	Based on Mean	.310	1	159	.578
	Based on Median	.187	1	159	.666
	Based on Median and with adjusted df	.187	1	158.000	.666
	Based on trimmed mean	.255	1	159	.614

-Uji Kruskal-Wallis

#### Kruskal-Wallis Test

Ranks			
	Kegiatan Visite dan Konsultasi <i>Clinical Pathway</i>	N	Mean Rank
Biaya Riil	Dilakukan Visite Dokter Spesialis Saraf Pada Pasien Stroke Iskemik	159	81.03
	Dilakukan Visite Dokter Spesialis Saraf, Konsultasi Dokter Spesialis Bedah Saraf & KFR Pada Stroke Hemoragik	2	78.50
	Dilakukan Visite Dokter Spesialis Saraf, Konsultasi Dokter Spesialis Bedah Saraf Pada Stroke Hemoragik	1	162.00
Total		162	

**Test Statistics<sup>a,b</sup>**

Biaya Riil	
Kruskal-Wallis H	2.969
df	2
Asymp. Sig.	.227

a. Kruskal Wallis Test

b. Grouping Variable:  
Kegiatan Visite dan  
Konsultasi *Clinical*  
*Pathway*

- b. Hubungan Biaya *Riil* Dengan Kegiatan Terapi Obat *Clinical Pathway*  
- Uji Normalitas Kolmogorov-Smirnov

**One-Sample Kolmogorov-Smirnov Test**

		Unstandardized Residual
N		162
Normal Parameters <sup>a,b</sup>	Mean	.0000000
	Std. Deviation	2839536.66900572
	Most Extreme Differences	
	Absolute	.138
	Positive	.138
	Negative	-.084
Test Statistic		.138
Asymp. Sig. (2-tailed)		.000 <sup>c</sup>

a. Test distribution is Normal.

b. Calculated from data.

c. Lilliefors Significance Correction.

- Uji Homogenitas Levene

**Test of Homogeneity of Variances**

		Levene Statistic	df1	df2	Sig.
Biaya Riil	Based on Mean	2.714	25	67	.001
	Based on Median	1.409	25	67	.135
	Based on Median and with adjusted df	1.409	25	16.673	.236
	Based on trimmed mean	2.615	25	67	.001

- Uji Kruskal-Wallis

### Kruskal-Wallis Test

#### Test Statistics<sup>a,b</sup>

	Biaya Riil
Kruskal-Wallis H	120.169
df	94
Asymp. Sig.	.036

a. Kruskal Wallis Test

b. Grouping Variable:  
Kegiatan Terapi Obat  
*Clinical Pathway*

#### Hypothesis Test Summary

	Null Hypothesis	Test	Sig.	Decision
1	The distribution of Biaya Riil is the same across categories of Kegiatan Terapi Obat Clinical Pathway.	Independent-Samples Kruskal-Wallis Test	.036	Reject the null hypothesis.

Asymptotic significances are displayed. The significance level is .05.

- c. Hubungan Biaya *Riil* Dengan Rehabilitasi/Fisioterapi
  - Uji Normalitas Kolmogorov-Smirnov

#### One-Sample Kolmogorov-Smirnov Test

		Unstandardized Residual
N		162
Normal Parameters <sup>a,b</sup>	Mean	.0000000
	Std. Deviation	2785911.156
		01097
Most Extreme Differences	Absolute	.140
	Positive	.140
	Negative	-.074
Test Statistic		.140
Asymp. Sig. (2-tailed)		.000 <sup>c</sup>

a. Test distribution is Normal.

b. Calculated from data.

c. Lilliefors Significance Correction.

- Uji Homogenitas Levene

### Test of Homogeneity of Variances

		Levene Statistic	df1	df2	Sig.
Biaya Riil	Based on Mean	4.374	3	157	.005
	Based on Median	3.693	3	157	.013
	Based on Median and with adjusted df	3.693	3	153.340	.013
	Based on trimmed mean	4.233	3	157	.007

- Uji Kruskal-Wallis

### Kruskal-Wallis Test

		Ranks	
	Rehabilitasi/Fisioterapi	N	Mean Rank
Biaya Riil	Tidak (Stroke Iskemik)	26	69.46
	1-2 Hari (Stroke Iskemik)	110	79.63
	>2 Hari (Stroke Iskemik)	23	100.83
	1-2 Hari (Stroke Hemoragik)	2	102.00
	>2 Hari (Stroke Hemoragik)	1	115.00
	Total	162	

### Test Statistics<sup>a,b</sup>

	Biaya Riil
Kruskal-Wallis H	6.683
df	4
Asymp. Sig.	.154

a. Kruskal Wallis Test

b. Grouping Variable:  
Rehabilitasi/Fisioterapi

### Lampiran 6. Kesesuaian Biaya *Riil* Dengan Tarif INA-CBG's

- Uji Normalitas G-4-14-I

#### One-Sample Kolmogorov-Smirnov Test

		Unstandardized Residual
N		56
Normal Parameters <sup>a,b</sup>	Mean	.0000000
	Std. Deviation	1960085.981
	Absolute	.190
Most Extreme Differences	Positive	.190
	Negative	-.143
Test Statistic		.190
Asymp. Sig. (2-tailed)		.000 <sup>c</sup>

a. Test distribution is Normal.

b. Calculated from data.

c. Lilliefors Significance Correction.

- Uji Normalitas G-4-14-II

#### One-Sample Kolmogorov-Smirnov Test

		Unstandardized Residual
N		235
Normal Parameters <sup>a,b</sup>	Mean	.0000000
	Std. Deviation	2127818.236
	Absolute	.146
Most Extreme Differences	Positive	.146
	Negative	-.101
Test Statistic		.146
Asymp. Sig. (2-tailed)		.000 <sup>c</sup>

a. Test distribution is Normal.

b. Calculated from data.

c. Lilliefors Significance Correction.

- Uji Normalitas Shapiro-Wilk G-4-14-III

#### Tests of Normality

	Klasifikasi Biaya	Kolmogorov-Smirnov <sup>a</sup>			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
Total Biaya	Biaya INA-CBG's Kelas 1	.	2	.			
	Biaya INA-CBG's Kelas 2	.	2	.			
	Biaya INA-CBG's Kelas 3	.	9	.	.	9	.
	Biaya <i>Riil</i> Kelas 1	.260	2	.			

Biaya Riil Kelas 2	.260	2	.			
Biaya Riil Kelas 3	.258	9	.086	.905	9	.284

a. Lilliefors Significance Correction

- Uji Normalitas G-4-13-III

#### Tests of Normality<sup>a,c</sup>

	Klasifikasi Biaya	Kolmogorov-Smirnov <sup>b</sup>		
		Statistic	df	Sig.
Total Biaya	Biaya Riil Kelas 3	.260	2	.
	Biaya INA-CBG's Kelas 3	.	2	.

a. Total Biaya is constant when Klasifikasi Biaya = Biaya Riil Kelas 2. It has been omitted.

b. Lilliefors Significance Correction

c. Total Biaya is constant when Klasifikasi Biaya = Biaya INA-CBG's Kelas 2. It has been omitted.

- Uji Normalitas Total Biaya

#### One-Sample Kolmogorov-Smirnov Test

		Unstandardized Residual
N		324
Normal Parameters <sup>a,b</sup>	Mean	.0000000
	Std. Deviation	2274451.042
		51289
Most Extreme Differences	Absolute	.141
	Positive	.141
	Negative	-.062
Test Statistic		.141
Asymp. Sig. (2-tailed)		.000 <sup>c</sup>

a. Test distribution is Normal.

b. Calculated from data.

c. Lilliefors Significance Correction.

- Uji Homogenitas G-4-14-I

#### Test of Homogeneity of Variances

		Levene Statistic	df1	df2	Sig.
Total Biaya Riil	Based on Mean	5.016	5	50	.001
	Based on Median	3.427	5	50	.010
	Based on Median and with adjusted df	3.427	5	14.928	.029

	Based on trimmed mean	4.352	5	50	.002
--	-----------------------	-------	---	----	------

- Uji Homogenitas G-4-14-II

### Test of Homogeneity of Variances

		Levene Statistic	df1	df2	Sig.
Total Biaya	Based on Mean	32.484	5	229	.000
	Based on Median	24.836	5	229	.000
	Based on Median and with adjusted df	24.836	5	109.482	.000
	Based on trimmed mean	29.264	5	229	.000

- Uji Homogenitas G-4-14-III

### Test of Homogeneity of Variances

		Levene Statistic	df1	df2	Sig.
Total Biaya	Based on Mean	2.575	5	20	.059
	Based on Median	2.345	5	20	.079
	Based on Median and with adjusted df	2.345	5	8.000	.136
	Based on trimmed mean	2.612	5	20	.056

- Uji Homogenitas Total Biaya

### Test of Homogeneity of Variances

		Levene Statistic	df1	df2	Sig.
Total Biaya	Based on Mean	13.846	3	320	.000
	Based on Median	7.843	3	320	.000
	Based on Median and with adjusted df	7.843	3	212.577	.000
	Based on trimmed mean	12.100	3	320	.000

- Uji Kruskal-Wallis G-4-14-I

### Ranks

		Klasifikasi Biaya	N	Mean Rank
Total Biaya Riil	Biaya Riil Kelas 1		5	40.60
	Biaya Riil Kelas 2		11	29.36
	Biaya Riil Kelas 3		12	24.50



Biaya INA-CBG's Kelas 1	5	45.00
Biaya INA-CBG's Kelas 2	11	31.00
Biaya INA-CBG's Kelas 3	12	17.50
Total	56	

### Test Statistics<sup>a,b</sup>

Total Biaya Riil

Kruskal-Wallis H	14.602
df	5
Asymp. Sig.	.012

a. Kruskal Wallis Test

b. Grouping Variable:

Klasifikasi Biaya

- Uji Kruskall-Wallis G-4-14-II

### Ranks

	Klasifikasi Biaya	N	Mean Rank
Total Biaya	Biaya INA-CBG's Kelas 1	36	199.50
	Biaya INA-CBG's Kelas 2	26	156.50
	Biaya INA-CBG's Kelas 3	56	97.50
	Biaya Riil Kelas 1	36	127.00
	Biaya Riil Kelas 2	26	68.62
	Biaya Riil Kelas 3	55	84.78
	Total	235	

### Test Statistics<sup>a,b</sup>

Total Biaya

Kruskal-Wallis H	94.396
df	5
Asymp. Sig.	.000

a. Kruskal Wallis Test

b. Grouping Variable:

Klasifikasi Biaya

## - Uji ANOVA G-4-14-II

**ANOVA**

Total Biaya

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	83638901279 615.390	5	16727780255 923.078	7.443	.000
Within Groups	44951803705 000.000	20	22475901852 50.000		
Total	12859070498 4615.390	25			

## - Uji Kruskal-Wallis G-4-13-III

**Ranks**

	Klasifikasi Biaya	N	Mean Rank
Total Biaya	Biaya Riil Kelas 2	1	6.00
	Biaya Riil Kelas 3	2	3.00
	Biaya INA-CBG's Kelas 2	1	4.00
	Biaya INA-CBG's Kelas 3	2	2.50
	Total	6	

**Test Statistics<sup>a,b</sup>**

	Total Biaya
Kruskal-Wallis H	2.647
df	3
Asymp. Sig.	.449

a. Kruskal Wallis Test

b. Grouping Variable: Klasifikasi

Biaya

## - Uji Kruskal-Wallis Total

**Ranks**

	Klasifikasi Biaya	N	Mean Rank
Total Biaya	Biaya INA-CBG's Stroke Hemoragik	3	123.33
	Biaya INA-CBG's Stroke Iskemik	159	188.55
	Biaya Riil Stroke Hemoragik	3	193.33

Biaya Riil Stroke Iskemik	159	136.60
Total	324	

**Test Statistics<sup>a,b</sup>**

	Total Biaya
Kruskal-Wallis H	25.483
df	3
Asymp. Sig.	.000

a. Kruskal Wallis Test

b. Grouping Variable:  
Klasifikasi Biaya

**Kesesuaian Biaya Riil & INA-CBG's**

Stroke	Kelas	Biaya	Total Biaya	Selisih	
Hemoragik	2	Biaya Riil	16,805,700.00	-9471400.00	
		Biaya INA-CBG's	7,334,300.00		
	3	Biaya Riil	13,265,100.00	-1041300.00	
		Biaya INA-CBG's	12,223,800.00		
	Iskemik	1	Biaya Riil	37,040,500.00	-1948500.00
			Biaya INA-CBG's	35,092,000.00	
2		Biaya Riil	68,105,700.00	-1931900.00	
		Biaya INA-CBG's	66,173,800.00		
3		Biaya Riil	256,040,900.00	-195883700.00	
		Biaya INA-CBG's	60,157,200.00		
Iskemik		1	Biaya Riil	294,400,400.00	53838400.00
			Biaya INA-CBG's	348,238,800.00	
		2	Biaya Riil	171,025,900.00	44550500.00
			Biaya INA-CBG's	215,576,400.00	
		3	Biaya Riil	392,862,600.00	-5930600.00
			Biaya INA-CBG's	386,932,000.00	
1	Biaya Riil	13,208,700.00	11073500.00		
	Biaya INA-CBG's	24,282,200.00			
2	Biaya Riil	18,776,000.00	2037200.00		

	Biaya INA-CBG's	20,813,200.00	
3	Biaya Riil	56,565,900.00	21483900.00
	Biaya INA-CBG's	78,049,800.00	



## Lampiran 7. Faktor Yang Mempengaruhi Biaya Riil

### a. Uji Regresi Linier Berganda

		Coefficients <sup>a</sup>		Standardized		
		Unstandardized Coefficients		Coefficients	t	Sig.
Model		B	Std. Error	Beta		
1	(Constant)	3327910.031	1134057.989		2.935	.004
	Usia	-178028.676	163858.157	-.068	-1.086	.279
	Kode INA-CBG's	615093.979	290960.027	.121	2.114	.036
	Hak Kelas Perawatan	-843068.208	167145.101	-.307	-5.044	.000
	LOS	1985724.861	199119.874	.638	9.973	.000
	Jumlah Jenis Obat Tambahkan	230303.187	219286.150	.068	1.050	.295
	Peningkatan Kelas Rawat	-69945.832	234947.010	-.020	-.298	.766
	Jumlah Penyakit Penyerta	271825.725	193783.623	.082	1.403	.163
	Tindakan Diluar Clinical Pathway	221711.827	57310.541	.271	3.869	.000

a. Dependent Variable: Biaya Riil

